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5-FU cytotoxicity mechanism has been assigned both to the miss-incorporation of
fluoronucleotides into RNA and DNA and to the inhibition of thymidylate synthase.
5-FU is one of the most widely used chemotherapeutic drugs, although it has severe
side effects that may vary between patients. Pharmacogenetic studies related to 5-FU
have been traditionally focused on the rate-limiting catabolic enzyme, dihydropyrimidine
dehydrogenase that breaks 80–85% of 5-FU into its inactive metabolite. Choosing the
right dosing scheme and chemotherapy strategy for each individual patient remains
challenging for personalized chemotherapy management. In the general effort toward
reduction of colorectal cancer mortality, in vitro screening studies play a very important
role. To accelerate translation research, increasing interest has been focused on using
in vivo-like models such as three-dimensional spheroids. The development of higher
throughput assays to quantify phenotypic changes in spheroids is an active research
area. Consequently, in this study we used the microarray technology to reveal the HT-29
colorectal adenocarcinoma cells gene expression signature as response to 5-FU/OXP/FA
treatment in a state of the art 3D culture system. We report here an increased reactive
oxygen species production under treatment, correlated with a decrease in cell viability
and proliferation potential. With respect to the HT-29 cells gene expression under the
treatment with 5-FU/OXP/FA, we found 15.247 genes that were significantly differentially
expressed (p < 0.05) with a fold change higher that two-fold. Among these, 7136
genes were upregulated and 8111 genes were downregulated under experimental
conditions as compared to untreated cells. The most relevant and statistic significant
(p < 0.01) pathways in the experiment are associated with the genes that displayed
significant differential expression and are related to intracellular signaling, oxidative stress,
apoptosis, and cancer.
Keywords: colorectal cancer, 5-fluorouracil, oxaliplatin, dihydropyrimidine dehydrogenase, gene expression, DPD
polymorphism, personalized medicine
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INTRODUCTION
Antimetabolite drugs interfere with essential biosynthetic
processes or are incorporated into DNA and RNA
macromolecules inhibiting their normal function. The
fluoropyrimidine 5-fluorouracil (5-FU) does both. Briefly,
5-FU cytotoxicity mechanism has been assigned both to
the miss-incorporation of fluoronucleotides into RNA and
DNA and to the inhibition of thymidylate synthase (TS).
Consequently, 5-FU is converted intracellularly to three active
metabolites, namely: fluorodeoxyuridine monophosphate
(FdUMP), fluorodeoxyuridine triphosphate (FdUTP), and
fluorouridine triphosphate (FUTP) which trigger a series of
events that lead to the decrease of cell proliferation potential and
induce apoptosis.
Fluoropyrimidines, particularly 5-FU and its pro-drug
capecitabine, have been extensively used either as monotherapy
or combination therapy for the last five decades worldwide
(Ezzeldin and Diasio, 2004) as first line treatment for some
solid cancers including gastrointestinal tract and breast
(Loganayagam et al., 2010). However, even though the benefits of
fluoropyrimidine based chemotherapy are well known, adverse
drug reactions are of major clinical concern. Patients receiving
5-FU may experience severe myelosuppression, cardiac toxicity,
mucositis, and hand–foot syndrome (Yen and McLeod, 2007)
as well as nausea and vomiting. Furthermore, a high level of
toxicity (grade 3–4) may encounter in up to 31–34% of patients
receiving 5-FU, with 0.5% mortality (Meta-Analysis Group in
Cancer et al., 1998).
Capecitabine pro-drug is activated through a multistep
process that is transformed to 5-FU preferentially in tumor cells
and thus was introduced in breast and colorectal cancer (CRC)
chemotherapy to reduce the fluoropyrimidine induced toxicity
(van Kuilenburg, 2004). However, 5-FU is one of the most widely
used chemotherapeutic drugs, although it has severe side effects
that may vary between patients (van Kuilenburg et al., 2003;
Abbreviations: 2D, two-dimensional; 3D, three-dimensional; 5-FU, 5-fluorouracil;
ABCC3, ATP binding cassette subfamily C member 3; ABCC5, ATP binding
cassette subfamily C member 5; ABCG2, ATP-binding cassette sub-family G
member 2; ACCMP, advanced colorectal cancer meta-analysis project; CDA,
cytidine deaminase; CES1, carboxylesterase 1; CH2THF, folate; CRC, colorectal
cancer; Cy3, cyanine-3; DCFH-DA, 2′,7′-dichlorofluorescein diacetate; DHFR,
dihydrofolate reductase; DHFU, dihydrofluorouracil; DMEM, Dulbecco’s
modified Eagle‘s Medium; DNA, Deoxyribonucleic acid; DPD, dihydropyrimidine
dehydrogenase; DPYD, dihydropyrimidine dehydrogenase; ERCC1, Excision
Repair Cross-Complementation Group 1; ERCC2, excision repair cross-
complementation group 2; ERCC4, Excision Repair Cross-Complementation
Group 4; FA, folinic acid (5′-formyltetrahydrofolate); FBS, fetal bovine serum;
FdUMP, fluorodeoxyuridine monophosphate; FdUTP, fluorodeoxyuridine
triphosphate; FPGS, folylpolyglutamate synthase; FUDP, fluorouridine
diphosphate; FUMP, fluorouridine monophosphate; FUR, fluorouridine; FUTP,
fluorouridine triphosphate; GGH, gamma-glutamyl hydrolase; GSTP1, glutathione
S-transferase; IPA, Ingenuity Pathway Analysis; LV, leucovorin; MCTSs, multi
cellular tumor spheroids; MTHFR, methylenetetrahydrofolate reductase; NER,
nucleotide excision repair; OXP, oxaliplatin; PPAT, phosphoribosyl pyrophosphate
amidotransferase; Pt-DNA, Platinum-DNA; Pt-GG, Pt-Guanine-Guanine; RNA,
Ribonucleic acid; ROS, reactive oxygen species; SMUG1, single-strand selective
monofunctional uracil DNA glycosylase; TDG, thymine DNA glycosylase; TK1,
thymidine kinase 1; TS, thymidylate synthase; UCK1, uridine-cytidine kinase 1;
UMPS, uridine monophosphate synthase; UPP1, uridine phosphorylase 1.
Lazar et al., 2004; Ciccolini et al., 2006). Choosing the right
dosing scheme and chemotherapy strategy for each individual
patient remains challenging for personalized chemotherapy
management (Ciccolini et al., 2004). To further improve patient
outcomes, new regimens containing cytotoxic agents such as
oxaliplatin (OXP) and irinotecan have been introduced (de
Gramont, 2000). The commonly used combination of these drugs
is known as FOLFOX [leucovorin (LV), 5-FU, and OXP] or
FOLFILI (LV, 5-FU, and irinotecan).
Though FOLFOX and FOLFIRI treatments have improved
survival and response rates in patients with metastatic disease (de
Gramont, 2000; Goldberg et al., 2004; Thirion et al., 2004; Van
Cutsem et al., 2009), 5-FU-based treatment may be demanding
because of patient efficacy and toxicity variability (Diasio and
Harris, 1989; McLeod et al., 2003). While variability may be
linked to multiple clinical factors, genetic differences might also
contribute to drug response.
Pharmacogenetic studies related to 5-FU have been
traditionally focused on the rate-limiting catabolic enzyme,
dihydropyrimidine dehydrogenase (DPD). DPD is one of the
pivotal enzymes in the metabolism pathway of 5-FU, which
breaks 80–85% of 5-FU into inactive DHFU metabolite (Diasio
and Harris, 1989). Thus, DPD’s activity and its gene expression
provide a promising instrument to predict the pharmacokinetics
and also the chemotherapeutic toxicity of 5-FU.
OXP is an anticancer agent that acts by the formation
of Platinum-DNA (Pt-DNA) adducts resulting in DNA-strand
breaks (Woynarowski et al., 1998). These Pt-DNA adducts
typically are in the form of Pt-Guanine-Guanine (Pt-GG)
bonding (Chaney et al., 2004). Ultimately, Pt-DNA complexes at
the nucleotide level will either activate DNA repair mechanisms
[nucleotide excision repair (NER) pathway] or apoptotic
pathways.
Leucovorin or folinic acid (FA, 5′-formyltetrahydrofolate) has
been used to expand the intracellular concentration of reduced
folate (CH2THF) which is necessary for optimal binding of
FdUMP, one of the 5-FU’s active metabolite, to TS. FA enters the
cell via the reduced folate carrier and is anabolized to CH2THF,
which is then polyglutamated by folylpolyglutamate synthase.
Polyglutamation not only increases the cellular retention of
CH2THF, but also enhances the stabilization of its ternary
complex with TS and FdUMP (Dolnick and Cheng, 1978;
Radparvar et al., 1989). Furthermore, the Advanced Colorectal
Cancer Meta-analysis Project (ACCMP) showed that 5-FU/FA
generated significantly superior response rates compared with
single agent 5-FU (23 vs. 11%). However, this didn’t improve the
overall survival (The Meta-Analysis Group in Cancer, 1992).
In the general effort toward reduction of CRC mortality, in
vitro screening studies play a very important role. Yet, preclinical
cancer models predicting clinical treatment outcome are needed
in the development of new therapeutic approaches. Nowadays,
much effort is being spent on the design of advanced preclinical
models that could provide a robust solution to bridge the
gap between good preclinical results and success in clinical
practice. Standard two-dimensional (2D) cell cultures for effect
testing of anticancer agents are simple and convenient, but
present significant limitations in reproducing the complexity and
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pathophysiology of in vivo tumor tissue (Galateanu et al., 2016).
To accelerate translation research, increasing interest has been
focused on using three-dimensional (3D) spheroids for modeling
cancer and tissue biology.
Development of higher throughput assays to quantify
phenotypic changes in spheroids is an active research area
(Galateanu et al., 2016). Furthermore, microarray technology has
the potential both to identify novel genes that have key roles
in mediating resistance to 5-FU-based chemotherapy and also
reveal the gene expression signature of CRC cells as response to
5-FU-based chemotherapy. Such genes might be therapeutically
valuable as predictive biomarkers of 5-FU chemosensitivity
and/or provide new molecular targets that overcome drug
resistance.
In this context, we used the microarray technology to reveal
the HT-29 colorectal adenocarcinoma cells gene expression
signature as response to 5-FU/OXP/FA treatment in a state of the
art 3D culture system.
MATERIALS AND METHODS
Cell Culture Model and Drugs Treatments
HT-29 human colon adenocarcinoma cells (American Type
Culture Collection) were cultured routinely at 37◦C under a
humidified atmosphere of 5% CO2 as a monolayer in Dulbecco’s
modified Eagle’s Medium (DMEM), supplemented with 10% fetal
bovine serum (FBS) and 1% penicillin—streptomycin. All the
studies were performed using a scaffold free 3D culture system. In
this view, multi cellular tumor spheroids (MCTSs) were obtained
as previously described (Galateanu et al., 2016) during 4 days of
culture after seeding 5× 103 cells / 20 µl in 384 Perfecta hanging
drop culture plates.
For the described experiments the treatments concentrations
were previously optimized on this particular 3D culture model
(Galateanu et al., 2016). Briefly, on the 5th day of culture
some MCTSs were left untreated and some MCTSs were treated
with 5-fluorouracil (5-FU, SIGMA Aldrich, code 1001963413),
oxaliplatin (OXP, SIGMA Aldrich, code 1001946478) and folinic
acid (FA, SIGMAAldrich, code 101563489) for 24 h, 3 and 7 days,
as described in Table 1.
Live/Dead Fluorescence Microscopy Assay
HT-29 MCTSs morphology and dimensions as well as
treatments anti-proliferative potential were investigated
by Live/Dead (Invitrogen, Foster, CA) fluorescence
assay. In this view, CMCTSs, T1MCTSs, T2MCTSs, and
T3MCTSs were stained for 20 min at room temperature
TABLE 1 | MCTSs treatment.
Sample Treatment Time Abbreviation
Control Untreated NA CMCTSs
5-FU+OXP+AF 15 mM 5-FU + 500 µM + 2 mM FA 24 h T1MCTSs
5-FU+OXP+AF 15 mM 5-FU + 500 µM + 2 mM FA 3 days T2MCTSs
5-FU+OXP+AF 15 mM 5-FU + 500 µM + 2 mM FA 7 days T3MCTSs
and darkness with a solution containing calceinAM and
ethidium bromide, prepared according to the manufacturer’s
recommendation.
The Measurement of Intracellular Reactive
Oxygen Species (ROS)
ROS production was assessed using fluorescent 2′,7′-
dichlorofluorescein diacetate (DCFH-DA) (Sigma-Aldrich).
In this view, CMCTSs and T3MCTSs were dissociated by
tripsin/EDTA treatment for 15 min at 37◦C and the resulting
cells were incubated with 10 µM DCFH-DA for 30 min at 37◦C.
The fluorescence of the resulting dichlorofluoroscein (DCF) was
quantified using a fluorimeter (Jasco FP 750), with excitation and
emission wavelengths of 485 and 530 nm, respectively.
Analysis of Gene Expression by Microarray
CMCTSs and T3MCTSs were dissociated in individual cells by
trypsin/EDTA treatment for 15 min at 37◦C and then subjected
to RNA isolation and purification using the PureLink RNA
Mini Kit (Ambion, Life Technologies, Foster City, CA, USA—
Thermo Fisher Scientific), according to the manufacturer’s
protocols. Further, the RNA samples were tested for integrity on
BioAnalyzer 2100 (Agilent Technologies, Waldbronn, Germany)
and purity on NanoDrop 8000 spectrophotometer (Thermo
Fisher Scientific). Total RNA was converted intro cyanine—
3 (Cy3) labeled cRNA using the One—Color Low Input
Quick Amp Labelling Kit (Agilent Technologies) according
to the manufacturer’s instruction, followed by RNAeasy Mini
Kit (Qiagen) purification. The cRNA concentration and the
dye incorporation were assessed with a NanoDrop 8000
Spectrophotometer (Thermo Fisher Scientific). The samples were
hybridized using Agilent Gene Expression Hybridization Kit
(Agilent Technologies), following the manufacturer’s instruction.
Briefly, 600 ng of Cy3—labeled fragmented cRNAwas hybridized
overnight (65◦C, 17 h) to SurePrint G3 Human GE 8 × 60
k microarray slides in a rotating Agilent hybridization oven.
After hybridization, microarray slides were washed in Washing
Solutions I and II according to the producer’s wash buffer kit
instructions (Agilent Technlogies) and scanned immediately on
the Agilent DNA Microarray Scanner Model G2505C using
default one color scan settings. The quantification of the scanned
microarray images was done with Feature Extraction Software
12.0 (Agilent Technologies) using default settings.
The obtained data were further exported in GeneSpring
GX 13.0 (Agilent Technologies). The raw signals were log
transformed and normalized using Quantile normalization
method, with a threshold set at 1.0. For each probe, the median
of the log summarized value from the control samples was
calculated and subtracted from each of the samples to get
transformed baseline. The parameter values for experimental
grouping were set as treated with 5-FU + OXP + FA and
untreated (control probes). Probes that present compromised
and non-detected flags were filtered out using the Filter Probesets
by flags options available in GeneSpring GX 13.0. The obtained
results were further filtered on confidence using Moderated
t-test with a p-value cut-off set at 0.05, using Benjamini—
Hochberg multiple testing correction. The results obtained
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were further used to generate the list of statistically significant
differentially regulated genes between treated MCTS and control
MCTS, using a fold change higher than two-fold. The graphical
representation of the distribution of the fold changes and
their associated p-values as a volcano plot, was also generated
using GeneSpring GX 13.0 (Agilent Technologies). To further
characterize the biological pathways that are significant enriched
based on the list of statistically significant differentially expressed
genes, Single Experiment Analysis in GeneSpring GX 13.0 was
performed using a p-value cut-off set at 0.05. More, in order
to determine biologically significant networks and canonical
pathways modulated by our treatment regimen, we exported the
list of significant differentially expressed genes (p < 0.05) with a
fold change higher than 6 from GeneSpring GX 13.0 to Ingenuity
Pathway Analysis Software (Qiagen).
Statistical Analysis
The fluorimetric data obtained were statistically analyzed using
GraphPad Prism 3.03 Software, one-way ANOVA, Bonferroni
test. All the experiments were performed with n = 3 biological
replicates and each data set is presented as the average of three
replicates (mean± standard deviation). Level of significance was
p < 0.05.
RESULTS
The Measurement of Intracellular Reactive
Oxygen Species (ROS)
Intracellular reactive oxygen species (ROS) production by the
HT-29 cells in MCTSs as response to 5-FU + OXP + FA
treatment was evaluated in our experimental conditions. Our
results show that 5-FU + OXP + FA treatment generated high
levels of ROS in HT-29 adenocarcinoma cells, as the T3MCTSs
displayed a significantly increased (p < 0.001) level of ROS as
compared with CMCTSs (Figure 1).
This difference in ROS production indicates that the 5-FU +
OXP + FA treatment induced the oxidative response which
enhanced the formation of a considerable amount of free radicals.
FIGURE 1 | ROS relative levels in untreated MCTSs (CMCTSs) and in
MCTSs treated for 7 days with 5-FU + OXP + FA (T3MCTSs). ***p <
0.001 ROS relative level in T3MCTSs vs. CMCTSs.
The ROS generated could be responsible for damaging effects
on proteins and lipids, and could also alter the cell membrane
integrity of HT-29 cells, inducing a decrease in cell viability.
Regarding this particular aspect, we assessed the proliferative
status of HT-29 cells in MCTSs as response to 5-FU +
OXP + FA treatment by using the Live/Dead fluorescence
microscopy assay. In this view, CMCTSs, T1MCTSs, T2MCTSs,
and T3MCTSs were double stained with calceinAM and ethidium
bromide to highlight both the living and the dead cells in the
3D Spheroids. The images were captured using an Olympus
IX73 fluorescence inverted microscope and the CellF software
(Figure 2).
The captured images revealed the overall morphology of
the MCTSs during 7 days of treatment as well as the
distribution of the living and the dead cells inside the 3D
structures. Consequently, a compact spheroid consisting in
bright green living cells was found in the untreated sample.
After 24 h of treatment some dead cells were identified in
the core of the MCTSs. Two days later, the diameter of
the MCTSs decreased as compared to CMCTSs or T1MCTSs
and only a thin layer at the periphery displayed live cells.
Moreover, after 1 week of treatment we found that the
spheroids were disintegrated and the ratio between the living
and dead cells was significantly in the favor of the dead cells
(Figure 2).
Microarray Gene Expression Profiling of
MCTSs Treated with 5-FU + OXP + FA
Gene expression microarray analysis was employed to identify
the molecular changes occurring during 7 days of MCTSs
exposure to 5-FU + OXP + FA treatment (T3MCTSs) in
comparison with untreated MCTSs (CMCTSs). After performing
moderated t-test analysis with Bonferroni correction, the
screening process led to the identification of 15.247 genes
that were significantly differentially expressed (p < 0.05)
with a fold change higher that two-fold. Among these, 7136
genes were upregulated and 8111 genes were downregulated
T3MCTSs as compared with CMCTSs. The distribution of the
fold changes and their associated p-values in these genes
was graphically represented using the volcano plot shown in
Figure 3.
Furthermore, we analyzed the effects of 5-FU + OXP + FA
treatment on colorectal adenocarcinoma-related key genes in our
HT-29 MCTSs study model, focusing on genes correlated with
chemosensitivity or prognosis in colorectal adenocarcinoma. Our
results show that the expression of critical genes encoding DNA
excision repair proteins was significantly decreased by 5-FU +
OXP+ FA treatment. Such examples include the Excision Repair
Cross-Complementation Group 1 (ERCC-1, −4.6-fold) and
the Excision Repair Cross-Complementation Group 4 (ERCC-
4,−10.6-fold).
5-FU + OXP + FA treatment also influenced the mRNA
levels of genes involved in 5-FU metabolic pathway, including
dihydropyrimidine dehydrogenase (DPYD, −6.7-fold), ATP-
binding cassette sub-family G member 2 (ABCG2, −9.9-fold),
carboxylesterase 1 (CES1, +3-fold), uridine phosphorylase
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FIGURE 2 | Fluorescence microscopy images revealing the HT-29 MCTSs stained with calceinAM (green) for living cells and ethidium bromide (red) for
dead cells after no treatment (CMCTSs) and after 24 h, 3 and 7 days of exposure to 15 mM 5-FU + 500 µM + 2 mM FA (T1MCTSs, T2MCTSs, and
T3MCTSs, respectively).
FIGURE 3 | Volcano plot showing the distribution of the gene
expression fold changes of the T3MCTSs compared with CMCTSs.
Genes with absolute fold change ≥2 and p < 0.05 are indicated in red.
1 (UPP1, +4.1-fold), cytidine deaminase (CDA, −15.7-
fold), uridine-cytidine kinase 1 (UCK1, −8.6-fold), uridine
monophosphate synthase (UMPS, −2.4-fold), phosphoribosyl
pyrophosphate amidotransferase (PPAT,+2.3-fold), thymidine
kinase 1 (TK1, −15.5-fold), ATP binding cassette subfamily
C member 5 (ABCC5, −15.36-fold), ATP binding
cassette subfamily C member 3 (ABCC3, −15.29-fold),
methylenetetrahydrofolate reductase (MTHFR, −3.4-fold),
folylpolyglutamate synthase (FPGS, −4.1-fold), gamma-
glutamyl hydrolase (GGH, −7.8-fold), dihydrofolate reductase
(DHFR, −15.1-fold), excision repair cross-complementation
group 2 (ERCC2, −11.4-fold), thymine DNA glycosylase
(TDG, +4.34-fold), single-strand selective monofunctional
uracil DNA glycosylase (SMUG1, −3.4-fold), and thymidylate
synthese (TS, −6.7-fold).
Identification of Biological Pathways
Affected by 5-FU + OXP + FA
The most important pathways associated with the genes that
displayed significant differential expression between T3MCTSs
and untreated CMCTSs (p < 0.05, fold change <2) were identified
using the Single Experiment Analysis Tool in GeneSpring GX
13.0 and public pathway database. Consequently, as shown
in Table 2, our data reveal that most of the relevant and
statistic significant (p < 0.01) pathways in the experiment are
related to intracellular signaling, oxidative stress, apoptosis, and
cancer.
In order to assess the molecular functions and canonical
pathways modulated by 5-FU + OXP + FA treatment, the
significant differentially expressed genes (p < 0.05) with a
fold change >6 were uploaded to Ingenuity Pathway Analysis
(IPA). The analysis of the canonical pathways revealed that
a large number of canonical pathways are modulated by the
treatment with 5-FU + OXP + FA. The top five pathways
are represented in Table 3, along with their respective p-
values and ratio of the number of genes in the differential
expression gene list under given experimental conditions over
the total number of genes found in the respective canonical
pathway.
Furthermore, IPA analysis showed that the most significant
cellular and molecular functions affected by 5-FU + OXP + FA
treatment in HT-29 cells grown in MCTSs were related to cancer,
organismal injury and abnormalities, gastrointestinal diseases,
cell cycle and cellular growth, and proliferation.
In our experiment, after 7 days of treatment with 5-FU +
OXP + FA, PPAT gene expression in T3MCTSs was significantly
upregulated as compared to CMCTSs, while UMPS gene
expression was found significantly downregulated (Figure 4).
Furthermore, only UPP1 and UCK1 genes expression were
found significantly upregulated and downreguated, respectively.
TK1 gene expression was found in our experimental conditions
highly downregulated (Figure 4). Additionally, we report a
decrease in DPYD gene expression in T3MCTSs as compared
to CMCTSs (Figure 4). Nevertheless, ERCC1 gene expression was
significantly downregulated in T3MCTSs as compared to CMCTSs.
Consequently, at a global level, the genes involved in this
processes are down regulated in T3MCTSs as compared with the
CMCTSs.
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FIGURE 4 | 5-FU metabolism. Genes significantly up- or down-regulated by 5-FU + OXP + FA are represented in yellow boxes: ABCC2, ATP binding cassette
subfamily C member 2; CES1, carboxylesterase 1; UPP1, uridine phosphorylase 1; CDA, cytidine deaminase; DPD, dihydropyrimidine dehydrogenase; UMPS, uridine
monophosphate synthase; PPAT, phosphoribosyl pyrophosphate amidotransferase; TK1, thymidine kinase 1; UCK1, uridine-cytidine kinase; ABCC5, ATP binding
cassette subfamily C member 5; ABCC3, ATP binding cassette subfamily C member 3; TYMS, thymidylate synthase; ERCC2, excision repair
cross—complementation group 2; TDG, thymine DNA glycosylase; SMUG1, single-strand selective monofunctional uracil DNA glycosylase; MTHFR,
methylenetetrahydrofolate reductase; GGH, gamma—glutamyl hydrolase; DHFR, dihydrofolate reductase; and FPGS, folylpolyglutamate synthase.
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TABLE 2 | Relevant pathways modulated by 5-FU + OXP + FA treatment (p < 0.01).
Pathway name p-value Matched entities Total pathway entities
Hs_AMPK_Signaling_WP1403_79471 8.28E-11 45 68
Hs_Apoptosis_Modulation_and_Signaling_WP1772_80459 2.42E-08 52 95
Hs_Apoptosis_WP254_80450 4.17E-09 50 87
Hs_Benzo(a)pyrene_metabolism_WP696_72081 0.0090 6 9
Hs_DNA_Damage_Response_WP710_79974 8.78E-09 62 114
Hs_DNA_Damage_Reversal_WP1804_83251 0.0089 5 6
Hs_EGF-EGFR_Signaling_Pathway_WP437_79266 3.82E-09 82 162
Hs_Fluoropyrimidine_Activity_WP1601_82222 2.16E-07 24 34
Hs_Folate-Alcohol_and_Cancer_Pathway_WP1589_82223 0.00901 6 8
Hs_Gastric_Cancer_Network_1_WP2361_84551 3.62E-06 20 29
Hs_Integrated_Cancer_Pathway_WP1971_82939 4.51E-05 26 49
Hs_MAPK_Signaling_Pathway_WP382_79951 3.84E-11 89 168
Hs_Oncogene_Induced_Senescence_WP3308_83246 0.0098 12 26
Hs_Oxidative_Stress_Induced_Senescence_WP3404_83222 7.05E-07 49 99
Hs_Oxidative_Stress_WP408_78546 3.54E-04 18 30
Hs_Senescence_and_Autophagy_in_Cancer_WP615_81193 5.87E-04 47 109
The matched entity value represents the total number of genes differentially expressed in a pathway in given experimental conditions compared with the total number of entities of the
pathway in the database.
TABLE 3 | Top five canonical pathways identified with Ingenuity Pathway
Analysis (IPA) in T3MCTSs.
Canonical Pathway P-value Ratio
Molecular mechanism of cancer 2.44E−07 0.236
Xenobiotic metabolism signaling 6.9E−05 0.223
Noradrenaline and adrenaline degradation 7.68E−05 0.395
Glycogen degradation II 1.82E−04 0.636
Putrescine degradation III 1.95E−04 0.476
The ratio value refers to the number of genes in the differential expression gene list under
given experimental conditions over the total number of genes found in the respective
canonical pathway.
DISCUSSIONS
5-FU is converted in the hepatocytes into three main active
metabolites: fluorodeoxyuridine monophosphate (FdUMP),
fluorodeoxyuridine triphosphate (FdUTP), and fluorouridine
triphosphate (FUTP). The main mechanism of 5-FU activation
is conversion to fluorouridine monophosphate (FUMP), either
directly by phosphoribosyl pyrophosphate amidotransferase
(PPAT) and uridine monophosphate synthase (UMPS) or via
fluorouridine (FUR) through the sequential action of uridine
phosphorylase (UPP) and uridine kinase (UCK). An alternative
activation pathway involves the thymidine phosphorylase
catalyzed conversion of 5-FU to fluorodeoxyuridine (FUDR),
which is then phosphorylated by thymidine kinase (TK)
to FdUMP. Next, FUMP is phosphorylated to fluorouridine
diphosphate (FUDP), which can be either further phosphorylated
to the active metabolite fluorouridine triphosphate (FUTP), or
converted to fluorodeoxyuridine diphosphate (FdUDP) by
ribonucleotide reductase (RRM). In turn, FdUDP can either
be phosphorylated or dephosphorylated to generate the active
metabolites FdUTP and FdUMP, respectively.
Dihydropyrimidine dehydrogenase (DPD)-mediated
conversion of 5-FU to dihydrofluorouracil (DHFU) (Heggie
et al., 1987) is the rate-limiting step of 5-FU catabolism in normal
and tumor cells. Up to 85% of administered 5-FU is catabolized
by DPD in the liver. However, genetic polymorphisms in DPYD
results in wide inter-individual variation inDPD activity (Etienne
et al., 1995). A patient with partial or complete DPD deficiency
will accumulate active metabolites and could suffer serious
toxicity or even rare fatality, when exposed to fluoropyrimidines.
Consequently, the genetic approach to DPD-associated toxicity
was considered promising, as deleterious variants were found
in the DPD coding gene (DPYD, chromosome 1p22). Three
DPYD variants (IVS14 + 1G>A, c.2846A>T, and c.1679T>G)
were associated with fluoropyrimidine-induced toxicity (van
Kuilenburg, 2004). Furthermore, subsequent analysis on large
cohorts of patients suffering from 5-FU toxicity and control
individuals demonstrated that DPYD has been previously
reported as highly polymorphic (van Kuilenburg, 2004). In
vitro studies revealed that DPD overexpression in cancer cell
lines is correlated with 5-FU resistance (Takebe et al., 2001).
Furthermore, high levels of DPD mRNA expression in CRC
have also been demonstrated to interact with resistance to 5-FU
(Salonga et al., 2000), probably due to the higher DPD-mediated
degradation of 5-FU in these tumors. Additionally, DPD,
TS, and Thymidine phosphorylase (TP) might be considered
independent predictive markers of 5-FU response and that the
measurement of all these three markers markedly enhanced
the possibility to predict tumor response to 5-FU-based
chemotherapy (Salonga et al., 2000).
The reductive methylation of deoxyuridine monophosphate
(dUMP) to deoxythymidine monophosphate (dTMP)
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is catalyzed by TS, while the reduced folate 5,10-
methylenetetrahydrofolate (CH2THF) is acting as the methyl
donor (Figure 4). This reaction provides the only de novo source
of thymidylate, which is necessary for DNA replication and
repair. The 36-kDa TS protein functions as a dimer, with two
subunits containing a nucleotide-binding site and a binding
site for CH2THF. The 5-FU metabolite FdUMP binds to the
nucleotide-binding site of TS, forming a stable ternary complex
with the enzyme and CH2THF, thereby blocking binding of the
normal substrate dUMP and inhibiting dTMP synthesis (Santi
et al., 1974; Sommer and Santi, 1974).
Preclinical studies have demonstrated that TS expression is
a key determinant of 5-FU sensitivity. Gene amplification of
TS with consequent increase in TS mRNA and protein has
been observed in cell lines that are resistant to 5-FU and
fluorodeoxyuridine (FUDR) (Johnston et al., 1992; Copur et al.,
1995). In our study we found TS significantly downregulated in
T3MCTSs as compared to CMCTSs.
The 5-FU metabolite FUTP is extensively incorporated
into RNA, disrupting normal RNA processing and function.
Significant correlations between 5-FU miss-incorporation into
RNA and loss of clonogenic potential have been shown in human
colon and breast cancer cell lines (Kufe and Major, 1981; Glazer
and Lloyd, 1982). 5-FU miss-incorporation can result in toxicity
to RNA at several levels. It not only inhibits the processing
of pre- rRNA into mature rRNA (Kanamaru et al., 1986;
Ghoshal and Jacob, 1994), but also disrupts post-transcriptional
modification of tRNAs (Randerath et al., 1983; Santi and
Hardy, 1987) and the assembly and activity of snRNA/protein
complexes, thereby inhibiting splicing of pre-mRNA (Doong and
Dolnick, 1988; Patton, 1993). In addition, rRNA, tRNA, and
snRNA all contain the modified base pseudouridine, and 5-FU
has been shown to inhibit the post-transcriptional conversion
of uridine to pseudouridine in these RNA species (Samuelsson,
1991). Consequently, 5-FU miss-incorporation can potentially
disrupt many aspects of RNA processing, leading to profound
effects on cellular metabolism and viability. At this level, our
results show a significant decrease of ERCC2 and SMUG1 genes
expression, with high impact on cell viability and proliferation
status.
The exact mechanism of synergism between 5-FU and OXP
is complex, but experimental observations suggest that OXP
can downregulate or inhibit DPD, slowing the catabolism of
5-FU (Fischel et al., 2002). Despite initial sensitivity to OXP,
most cancer cells will eventually develop resistance. The most
important mechanisms in OXP resistance seem to be related
to DNA repair: MMR, or nucleotide excision repair (NER).
NER pathway include excision repair cross-complementing
group 1 protein (ERCC1), xerodermapigmentosum
complementation group D protein (XPD, also known as
ERCC2), glutathione S-transferase P1 (GSTP1), and TS (Martin
et al., 2008). Cells that overexpress ERCC1, are resistant
to OXP.
Some recent studies (Oka et al., 2012) report on the 5-
FU induced gene mutation and chromosomal damage in TP53
mutated cells, but not in TP53 wild-type cells after 24 h of
treatment, probably due to the difference in gene expression
related to TP53 pathway, especially the induction of apoptosis
or cell cycle arrest after DNA damage. Additionally, according to
Gherman et al. (2012), the p53 expression in the OXP treated cells
results in antitumor effects that include inhibition of cell cycle
progression and induction of apoptosis through the modulation
of the expression of apoptosis and cell-cycle-related genes, and
the sensitization of tumor cells to chemotherapy.
CONCLUSIONS
In the present study, we demonstrated that 5-FU/OXP/FA
treatment inhibits HT-29 CRC cells growth within a modern
in vivo-like 3D culture system, in a time dependent manner,
sensitizing these cells to the chemotherapeutic agent in the
case of multiple dose administration strategy. This lead to
a significant decrease of the viable cells number and also
in the microtumor’s diameter reduction. The underlying
mechanisms of the treatment effects mainly involve the
suppression of the proliferative status and the induction of the
apoptosis.
With respect to the HT-29 cells gene expression under the
treatment with 5-FU/OXP/FA, we found 15,247 genes that
were significantly differentially expressed (p < 0.05) with a
fold change higher that two-fold. Among these, 7136 genes
were upregulated and 8111 genes were downregulated under
experimental conditions as compared to untreated cells.
The most relevant and statistical significant (p < 0.01)
pathways in the experiment were found to be associated with
intracellular signaling, oxidative stress, apoptosis, and cancer
related genes that displayed differential expression.
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